Glibenclamide

$ 1.00 /1KG

Min. Order1G
Purity98%
Cas No10238-21-8
Supply Ability100KG
Update time2019-07-06

career henan chemical co

7YR

China

Chemical Properties

Product Name	Glibenclamide
CAS No	10238-21-8
EC-No
Min. Order	1G
Purity	98%
Supply Ability	100KG
Release date	2019/07/06

AD68

Glibenclamide Basic information

Hypoglycemic agents Hypoglycemic effect Precautions Chemical properties Uses Hazards & Safety Information

Product Name:	Glibenclamide
Synonyms:	LABOTEST-BB LT00244861;GLYBENCLAMIDE;GLYBENZCYCLAMIDE;GLYBURIDE;GIBENCLAMIDE;GLIBENCLAMIDE;5-CHLORO-N-[4-(CYCLOHEXYLUREIDOSULFONYL)PHENETHYL]-2-METHOXYBENZAMIDE;5-CHLORO-N-[2-[4-[[[(CYCLOHEXYLAMINO)CARBONYL]AMINO]-SULFONYL]PHENYL]ETHYL]-2-METHOXYBENZAMIDE
CAS:	10238-21-8
MF:	C23H28ClN3O5S
MW:	494
EINECS:	233-570-6
Product Categories:	Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Organics;Amino Acids & Derivatis;Isotope Labeled Compounds;API's;Potassium channel;Ion Channels;Isotope Labelled Compounds;API;GLYNASE;Diabetes Research
Mol File:	10238-21-8.mol

Glibenclamide Chemical Properties

Melting point	173-175°C
density	1.1805 (rough estimate)
refractive index	1.6100 (estimate)
storage temp.	2-8°C
solubility	ethanol: soluble2mg/mL
pka	5.3(at 25℃)
Water Solubility	Soluble in ethanol (5 mg/mL), DMSO (25 mg/mL), chloroform (1:36), methanol (1:250), and DMF. Insoluble in water.
Merck	14,4478
InChIKey	ZNNLBTZKUZBEKO-UHFFFAOYSA-N
CAS DataBase Reference	10238-21-8(CAS DataBase Reference)
NIST Chemistry Reference	Glyburide(10238-21-8)

Safety Information

Hazard Codes	Xn
Risk Statements	20/21/22
Safety Statements	22-36/37/39-36-24/25
RTECS	YS4725200
HS Code	29350090
Toxicity	LD50 in rats and mice (g/kg): >20 orally; >12.5 i.p.; >20 s.c. (Mizukami)

Glibenclamide Usage And Synthesis

Hypoglycemic agents	Glibenclamide belongs to the second generation oral sulfonylurea drugs with the mechanism of action being similar as tolbutamide and the hypoglycemic effect being strongest among sulfonylurea drugs. Its intensity of action is about 200 to 250 times of that of Tolbutamide. It can selectively act on the pancreatic β-cells, promote insulin secretion; can enhance the hypoglycemic effect of exogenous insulin and strengthen the post-receptor effect of insulin. It has fast oral absorption with high protein binding rate. It begins to take effect after 30 minutes with the effect being strongest at 1.5 hours and the duration of 16 to 24 hours. It has a distribution volume of 0.1L/kg, plasma protein binding rate of 90% to 95% and half-life of 4 to 8 hours. It is mainly consumed by the liver metabolism with six metabolites. Two of them are known as hydroxylated compounds with no hypoglycemic effect and is mainly excreted from the urine and a small amount is excreted by the stool. It is clinically mainly used for the treatment of mild to moderate non-insulin dependent diabetes mellitus. Recently, an international study found that the commonly used diabetes drug glibenclamide can help the body's immune system to fight against certain bacterial infections, e.g. in the treatment of melioidosis, the mortality rate can be reduced by about half. Melioidosis is a disease prevalent in tropical areas such as Southeast Asia and northern Australia. It is caused by Burkholderia pseudomallei with the symptoms including sepsis and pneumonia. The mortality rate is high. Diabetic patients tend to be more susceptible to melioidosis, but the mortality rate is lower compared with other patients.
Hypoglycemic effect	Glibenclamide is currently one of the most commonly used drugs for the treatment of type 2 diabetes. Because this product has fast and strong effect, so the effect after the application remarkable, being able to have good control of blood sugar; being applicable for patients of high blood sugar who get bad efficacy when treated with other sulfonyl Urea hypoglycemic agents. Two commonly sulfonylurea oral hypoglycemic agents are glibenclamide and glimepiride, the comparison of hypoglycemic effect of them two are as follow: (1) The effect on glucose transport and metabolism: Glibenclamide and glimepiride can stimulate the key enzymes in the glucose metabolism and improve the glucose transporter (GLUT4) translocation/dephosphorylation to promote the glucose uptake of the surrounding tissue, specifically exhibited in glycogen synthesis and increased fat formation. Glycogen synthase and 3-phosphoglycerol fatty acyltransferase are the key enzymes in glycogen and fat synthesis, and glimepiride is more active than glibenclamide in activating these key enzymes, such as for activating glycogen synthase activity, glimepiride is 2.5 times that of glibenclamide; for the capability to activate lipase, glimepiride is 1.9 times that of glibenclamide. Glimepiride increased the expression of GLUT4 on the cell membrane by inducing dephosphorylation of GLUT4. (2) Effect on glycosylated-phosphatidylinositol-specific phospholipase (GPI-PLC): GPI is located in the outer layer of the cell membrane and participates in insulin signal transduction, which can interfere with glucose metabolism of muscle and adipocytes. GPI-PLC can shed the GPI, thereby improving the cell phosphorylation status. Insulin and sulfonylureas can activate GPI-PLC, helping muscle, adipose tissue for the uptake and transport of glucose. However, in the presence of insulin resistance, insulin itself is very difficult to activate GPI-PLC, but glimepiride can still activate the enzyme. In vitro and in vivo studies have shown that, glimepiride has the strongest pancreatic effect in sulfonylurea drugs, which can increase glucose synthesis by 2.5 times and fat synthesis by 4 times. The ratio of glimepiride to glibenclamide was 2: 1. Therefore, glimepiride has a lower secondary failure incidence than other sulfonylurea drugs.
Precautions	Glibenclamide should be started at low doses. During treatment, it should be regularly checked of the urine sugar, urine ketone body, urine protein and blood sugar, blood routine examination, liver and kidney function, vision, retinal blood vessels. (1) Patients of liver and kidney dysfunction, leukopenia, sulfa allergy, pregnant women and diabetes complicated by acidosis and acute infection should be disabled. (2) It can cause abdominal distension, abdominal pain, anorexia, nausea and other gastrointestinal reactions. It can also appear as allergy (skin erythema or urticaria), leukopenia, granulocyte deficiency, thrombocytopenia, hypoglycemia, etc., should be immediately discontinued and treated. Among them, hypoglycemia reaction is more common. (3) Glibenclamide and other sulfonylurea hypoglycemic agents can’t be combined with thiazide diuretics or glucocorticoids. (4) It should be avoided to taken together with anticoagulant drugs such as dicoumaroline. (5) When combined with phenylbutazone, the hypoglycemic effect can be enhanced, causing acute hypoglycemia. (6) Combination with sulfonamides can enhance both the effect and toxicity of glibenclamide, not suitable for use. (7) Combination with chloramphenicol can also enhance the effect and toxicity of this product; combination of two drugs demands dose adjustment according to the patient's blood sugar levels, otherwise can cause hypoglycemic shock. (8) Sulfonylurea drugs can enhance the toxicity of alcohol; alcohol should be avoided during treatment.
Chemical properties	It appears as white crystalline powder. M.p. 168-173 ° C. It is insoluble in water, slightly soluble in ethanol, acetone and chloroform.
Uses	Hypoglycemic agents with stronger effect than toluene sulfonylurea; used for the treatment of mild, non-insulin-dependent diabetes;
Hazards & Safety Information	Category : Toxic substances Toxic classification: poisoning Acute toxicity: Intraperitoneal-rat LD50: 3750 mg/kg; Oral-mouse LD50: 3250 mg/kg Flammability Hazardous characteristics : Thermal decomposition releases toxic nitrogen oxides, sulfur oxides, chloride fumes Storage and transport characteristics: Treasury: low temperature, ventilated and dry Extinguishing agent : water, carbon dioxide, foam, dry powder
Chemical Properties	White Crystalline Powder
Uses	antihyperglycemic
Uses	Glyburide is a second generation sulfonylurea with hypoglycemic activity. Glyburide is an antidiabetic.
Uses	An ATP-dependent KIR6 and CFTR Cl- channel blocker
Definition	ChEBI: An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Biological Activity	ATP-dependent K + channel (K ATP ) and CFTR Cl - channel blocker. Inhibits K ATP currents in the pancreas, causing an increase in intracellular Ca 2+ and insulin secretion. Inhibits recombinant CFTR Cl- channels with an IC 50 of 20 μ M.